Washington DC (Newswire) — BioInformant has launched the “Market for Stem Cell Exosomes – Products, Services, & Technologies,” a global strategic report targeting the growing demand for exosome therapeutics, diagnostics, and research tools.
Exosomes are rapidly gaining momentum as a strategy for accessing the therapeutic effects of stem cells without the risks and difficulties of administering the cells to patients. With exosome companies multiplying in number and exosome publications on the rise, it is clear that exosomes will play a crucial role in the cell therapy movement.
Based in Washington, DC, BioInformant is the first and only market research firm to specialize in the stem cell industry. With more than a decade of experience in tracking the stem cell industry (2006 to present), BioInformant has a robust database on which to base future market predictions. Written for companies developing exosome-related products and technologies, the report analyzes strategic opportunities for commercializing products involving exosomes derived from stem cells, as well as other cell sources.
Cade Hildreth, President/CEO of BioInformant says: “The market for stem cell exosomes is exploding and early-stage entrants are positioned to profit. This global strategic report resulted as a byproduct of the growing amount of consultation that we have been doing for clients who want to expand into this market area. In addition to analyzing key market metrics, we have been acquiring domain names (URLs) pertaining to exosomes, because it is clear that it is an early-stage market that is poised for rapid commercialization. Exosomes share many commonalities with cell therapeutics, but at a lower risk profile.”
The report features market leaders, including Codiak Biosciences, Capricor Therapeutics, Kimera Labs, ExCoBio, Evox Therapeutics, Exogenus Therapeutics, Exosome Diagnostics, Exosome Sciences, and ReNeuron, among others. It also features companies offering exosome-based research products, including Beckman Coulter, Exiqon, Lonza (acquired HansaBioMed Life Sciences and invested in Exosomics Siena), Miltenyi Biotec, SystemBio, Thermo Fisher, Qiagen, and more.
Founded in 2006, BioInformant is a U.S. based company whose reports are backed by a 60-Day Money Back Guarantee and supported by Research Analysts who provide strategic consultation to clients by phone, Skype, and in person. Unfortunately, most market research firms do not specialize in a market niche and hire foreign writers with little experience in the topic. In contrast, BioInformant specializes in stem cell market research, attracting market leaders that include GE Healthcare, Pfizer, and PerkinElmer, through specialized market knowledge.
Founded in 2006, BioInformant was launched in response to demand from customers wanting to make rapid product development decisions, pursue high-growth markets, and have a trustworthy source for market metrics to present to investors. Over the next 12 months, BioInformant plans to launch an growing portfolio of strategic reports for the stem cell industry and meet expanding demand from international clients by making its news site (BioInformant.com) multilingual.
For more information contact: Cade Hildreth President/CEO; (703) 859-7617 or [email protected]
BioInformant.com is the first and only market research firm to specialize in the stem cell industry. BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data